
What We’re Reading: FDA Reviews ALS Drug; Vaccines Lower Long COVID-19; New COTA President, CEO
The FDA accepts an application for a drug to treat amyotriphic lateral sclerosis (ALS) for review; vaccines have been found to reduce people’s risk for developing long COVID-19; COTA announces Miruna Sasu, PhD, as its new president and CEO.
FDA Reviews ALS Therapy After Patient Concerns
After the controversial approval of Aduhelm (aducanuma) for Alzheimer disease, the FDA may soon approve another medication for the treatment of amyotriphic lateral sclerosis (ALS) based on partial data, according to
Vaccines Found to Lower Risk of Long COVID-19
A growing body of evidence is showing that the risk of a mild case of COVID-19 turning into a long-term medical condition is significantly reduced for people who have been vaccinated against the virus compared to unvaccinated individuals, according to
Former J&J Executive Becomes New President, CEO of COTA
Former Johnson & Johnson (J&J) executive Miruna Sasu, PhD, MBA, has been appointed as the company’s new president and CEO, according to a
Newsletter
Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.